Best Healthcare Stocks this July 2026

Danaher Corporation (DHR) stands out as a global leader in life sciences solutions, offering a robust portfolio of instruments and consumables. Despite a challenging year with a -1.57% return and a 0.73% dividend yield, analysts have set a median price target of $230, reflecting confidence in its long-term potential. With strong ratings from HSBC (Buy) and Piper Sandler (Neutral), this company remains an attractive option for investors seeking reliable income from a financially healthy organization.

Eli Lilly & Co. (NYSE: LLY) stands out as a leading biopharmaceutical firm, particularly known for its innovative weight-loss and diabetes treatments. With a remarkable 5-year return of 428.66% and a solid 1-year return of 55.59%, it captures the attention of investors seeking long-term growth potential. Analysts maintain a strong outlook, setting a median 12-month price target of $1,270, with recommendations ranging from "Buy" to "Outperform." Investors looking for a robust addition to their portfolios may find Eli Lilly appealing, especially given its position among the "10 Safe Stocks to Buy for the Long Term in 2026." The company boasts a modest dividend yield of 0.55%, reflecting its commitment to returning value while continuing to innovate in the biopharmaceutical space. With strong analyst ratings and a focus on breakthrough therapies, LLY is well-positioned for future success.

Eli Lilly and Company (NYSE:LLY) is considered a strong long-term investment, with a recent price target raised to $1,251 by BofA, which maintains a Buy rating on the stock.

Zoetis, a leading player in animal health, specializes in developing vaccines and therapeutics for both pets and livestock, making it a compelling choice for investors interested in the sector. With a current dividend yield of 2.75%, the stock has faced challenges recently, showing a 1-year return of -51.30% and a 5-year return of -59.35%. Analysts remain cautious, holding a median 12-month price target of $115.00, with a projected range between $85.00 and $160.00, reflecting a B+ rating for the stock amidst the market fluctuations.

Analysts predict a target price for ZTS of $121.18 over the next 12 months, with a high of $165.65 and a low of $64.27.

Merck & Co. Inc. (MRK) stands out as a global leader in pharmaceuticals and animal health, particularly noted for its robust oncology portfolio. With a solid dividend yield of 2.92% and impressive one-year returns of 62.30%, the company is an attractive option for investors seeking reliable income and growth. Analysts maintain a positive outlook, with a median 12-month price target of $135.00 and strong ratings from firms like Wells Fargo and JP Morgan, indicating confidence in Merck’s future performance.

AbbVie Inc. stands out as a major biopharmaceutical player, particularly in immunology and neuroscience therapies, making it an attractive choice for investors seeking reliable income from financially healthy companies. With a solid dividend yield of 2.70% and impressive returns—37.96% over the past year and 122.58% over five years—this stock has garnered strong analyst ratings, including a Buy from Canaccord Genuity and an Overweight from Piper Sandler. Analysts have set a median 12-month price target of $260, reflecting confidence in AbbVie's growth potential.

Intuitive Surgical stands out as a leader in robotic-assisted surgical systems, targeting minimally invasive procedures. Despite a challenging year with a -24.17% return, the company has shown resilience with a 33.06% return over the past five years. Analysts maintain a favorable outlook, assigning a median price target of $580.00, with recommendations from firms like B of A Securities and Barclays to buy or maintain overweight positions.

Johnson & Johnson stands out as a diversified healthcare leader with a strong presence across pharmaceuticals, medical devices, and consumer health markets. The company boasts a solid dividend yield of 2.28% and has delivered impressive returns, including a 67.09% increase over the past year. Analysts have a positive outlook, with a median 12-month price target of $260, reflecting strong confidence in its ongoing growth trajectory.

The highest closing price for Johnson & Johnson stock was $247.11 on March 2, 2026.

For investors seeking diversified exposure to the healthcare sector, XLV (Health Care Select Sector SPDR Fund) is a strong choice, tracking top U.S. healthcare stocks. This ETF boasts a solid dividend yield of 1.69% and impressive returns of 19.72% over the past year and 27.37% over the last five years. Recognized for its focus on financially healthy companies, XLV offers a consistent income stream and has delivered outstanding performance, accumulating a total return of over 807% since its inception in 1998.

XLV has returned +16.13% over the past year and -1.35% year-to-date, with a total return of +807.43% since December 22, 1998, averaging +8.37% per year.